{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T16:04:48Z","timestamp":1785168288057,"version":"3.55.0"},"reference-count":42,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2017,6,22]],"date-time":"2017-06-22T00:00:00Z","timestamp":1498089600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2017,6,22]],"date-time":"2017-06-22T00:00:00Z","timestamp":1498089600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Hepatology"],"published-print":{"date-parts":[[2017,8]]},"abstract":"<jats:p>Patients with resolved hepatitis B virus (HBV) infection who are treated for hematological malignancies remain at risk for HBV reactivation. Because of conflicting studies about whether the antibody to hepatitis B surface antigen (anti\u2010HBs) protects against reactivation in patients with resolved infection (hepatitis B surface antigen negative) receiving chemotherapy for hematological malignancies, we conducted a meta\u2010analysis to determine if anti\u2010HBs reduces HBV reactivation risk. We sought English\u2010language studies through March 1, 2016, in Medline and other sources that examined reactivation in patients with resolved HBV infection receiving chemotherapy for hematologic malignancies. The absolute risks and odds ratio (OR) of reactivation with versus without anti\u2010HBs were estimated in random\u2010effects model meta\u2010analyses. In 20 studies involving 1,672 patients not receiving antiviral prophylaxis, the reactivation risk was 14% (95% confidence interval [CI] 9.4%\u201019%) in 388 patients who had antibodies to hepatitis B core antigen only versus 5.0% (95% CI 3.0%\u20107.0%) in 1,284 patients who also had anti\u2010HBs. Anti\u2010HBs reduced reactivation risk with a pooled OR of 0.21 (95% CI 0.14\u20100.32) versus patients with antibody to hepatitis B core antigen only. Similar results were found when limiting the analysis to rituximab chemotherapy (OR = 0.19, 95% CI 0.11\u20100.32) and lymphoma (OR = 0.18, 95% CI 0.11\u20100.28). <jats:italic toggle=\"yes\">Conclusion<\/jats:italic>: In patients with resolved HBV receiving chemotherapy for hematological malignancies without antiviral prophylaxis, anti\u2010HBs positivity is associated with a decreased risk of reactivation; HBV screening in this patient population should include the routine use of anti\u2010HBs, and those who are anti\u2010HBs\u2010negative should receive antiviral prophylaxis. Future studies should examine the effect of anti\u2010HBs serum titers, the potential role for booster vaccinations, and antiviral prophylaxis prior to chemotherapy in this patient population. (H<jats:sc>epatology<\/jats:sc> 2017;66:379\u2013388).<\/jats:p>","DOI":"10.1002\/hep.29082","type":"journal-article","created":{"date-parts":[[2017,1,27]],"date-time":"2017-01-27T15:53:20Z","timestamp":1485532400000},"page":"379-388","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":141,"title":["Role of surface antibody in hepatitis B reactivation in patients with resolved infection and hematologic malignancy: A meta\u2010analysis"],"prefix":"10.1097","volume":"66","author":[{"given":"Sonali","family":"Paul","sequence":"first","affiliation":[{"name":"Section of Gastroenterology,Center for Liver Diseases, The University of Chicago Medicine,Chicago,IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Dickstein","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology,Tufts Medical Center,Boston,MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akriti","family":"Saxena","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology,Boston Medical Center,Boston,MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norma","family":"Terrin","sequence":"additional","affiliation":[{"name":"Institute for Clinical Research and Health Policy Studies,Tufts Medical Center, and Biostatistics, Epidemiology and Research Design (BERD) Center, Tufts Clinical and Translational Science Institute, Tufts University,Boston,MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Viveiros","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology,Tufts Medical Center,Boston,MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethan M.","family":"Balk","sequence":"additional","affiliation":[{"name":"Brown Center for Evidence\u2010Based Medicine,Brown University School of Public Health,Providence,RI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John B.","family":"Wong","sequence":"additional","affiliation":[{"name":"Division of Clinical Decision Making,Tufts Medical Center,Boston,MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2017,6,22]]},"reference":[{"key":"hep29082-bib-0001-20241017","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1053\/j.gastro.2014.10.039","article-title":"American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy","volume":"148","year":"2015","journal-title":"Gastroenterology"},{"key":"hep29082-bib-0002-20241017","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1053\/j.gastro.2014.10.038","article-title":"American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy","volume":"148","year":"2015","journal-title":"Gastroenterology"},{"key":"hep29082-bib-0003-20241017","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/hep.27609","article-title":"Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune\u2010suppressing and anticancer drugs: just the tip of the iceberg?","volume":"61","year":"2015","journal-title":"Hepatology"},{"key":"hep29082-bib-0004-20241017","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1001\/jama.2015.2571","article-title":"Preventing hepatitis B reactivation due to immunosuppressive drug treatments","volume":"313","year":"2015","journal-title":"JAMA"},{"key":"hep29082-bib-0005-20241017","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/hep.23190","article-title":"Chronic hepatitis B: update 2009","volume":"50","year":"2009","journal-title":"Hepatology"},{"key":"hep29082-bib-0006-20241017","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1055\/s-0033-1345722","article-title":"Immunosuppression and HBV reactivation","volume":"33","year":"2013","journal-title":"Semin Liver Dis"},{"key":"hep29082-bib-0007-20241017","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1007\/s00520-012-1576-7","article-title":"Hepatitis B virus management to prevent reactivation after chemotherapy: a review","volume":"20","year":"2012","journal-title":"Support Care Cancer"},{"key":"hep29082-bib-0008-20241017","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/jvh.12402","article-title":"Hepatitis B reactivation in HBsAg\u2010negative\/HBcAb\u2010positive patients receiving rituximab for lymphoma: a meta\u2010analysis","volume":"22","year":"2015","journal-title":"J Viral Hepat"},{"key":"hep29082-bib-0009-20241017","doi-asserted-by":"crossref","first-page":"4769","DOI":"10.1002\/cncr.25253","article-title":"Reactivation of hepatitis B virus after rituximab\u2010containing treatment in patients with CD20\u2010positive B\u2010cell lymphoma","volume":"116","year":"2010","journal-title":"Cancer"},{"key":"hep29082-bib-0010-20241017","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1200\/JCO.2008.18.0182","article-title":"Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab","volume":"27","year":"2009","journal-title":"J Clin Oncol"},{"key":"hep29082-bib-0011-20241017","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1007\/s00277-011-1241-0","article-title":"Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative\/hepatitis B core antibody positive patients receiving rituximab\u2010containing combination chemotherapy without routine antiviral prophylaxis","volume":"90","year":"2011","journal-title":"Ann Hematol"},{"key":"hep29082-bib-0012-20241017","doi-asserted-by":"crossref","first-page":"951","DOI":"10.3324\/haematol.12557","article-title":"Hepatitis B virus\u2013related liver disease in isolated anti\u2010hepatitis B\u2010core positive lymphoma patients receiving chemo\u2010 or chemo\u2010immune therapy","volume":"93","year":"2008","journal-title":"Haematologica"},{"key":"hep29082-bib-0013-20241017","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta\u2010analysis of observational studies in epidemiology: a proposal for reporting. Meta\u2010analysis of Observational Studies in Epidemiology (MOOSE) group","volume":"283","year":"2000","journal-title":"JAMA"},{"key":"hep29082-bib-0015-20241017","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1002\/sim.3511","article-title":"Why add anything to nothing? The arcsine difference as a measure of treatment effect in meta\u2010analysis with zero cells","volume":"28","year":"2009","journal-title":"Stat Med"},{"key":"hep29082-bib-0017-20241017","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1002\/sim.2380","article-title":"A modified test for small\u2010study effects in meta\u2010analyses of controlled trials with binary endpoints","volume":"25","year":"2006","journal-title":"Stat Med"},{"key":"hep29082-bib-0018-20241017","first-page":"1","article-title":"Closing the gap between methodologists and end\u2010users: R as a computational back\u2010end","volume":"49","year":"2012","journal-title":"J Stat Softw"},{"key":"hep29082-bib-0019-20241017","first-page":"1","article-title":"Conducting meta\u2010analyses in R with the metafor package","volume":"36","year":"2010","journal-title":"J Stat Softw"},{"key":"hep29082-bib-0020-20241017","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/S1665-2681(19)30778-1","article-title":"Prospective study of hepatitis B virus reactivation in patients with hematological malignancies","volume":"14","year":"2015","journal-title":"Ann Hepatol"},{"key":"hep29082-bib-0021-20241017","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1093\/cid\/civ344","article-title":"Monitoring of hepatitis B virus (HBV) DNA and risk of HBV reactivation in B\u2010cell lymphoma: a prospective observational study","volume":"61","year":"2015","journal-title":"Clin Infect Dis"},{"key":"hep29082-bib-0022-20241017","doi-asserted-by":"crossref","first-page":"3736","DOI":"10.1200\/JCO.2014.56.7081","article-title":"Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab\u2010containing chemotherapy for lymphoma: a prospective study","volume":"32","year":"2014","journal-title":"J Clin Oncol"},{"key":"hep29082-bib-0023-20241017","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.3109\/10428194.2014.947606","article-title":"The risk of hepatitis B virus reactivation and the role of antiviral prophylaxis in hepatitis B surface antigen negative\/hepatitis B core antibody positive patients with diffuse large B\u2010cell lymphoma receiving rituximab\u2010based chemotherapy","volume":"56","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"hep29082-bib-0024-20241017","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1002\/jmv.23694","article-title":"Reactivation of hepatitis B virus in patients with undetectable HBsAg undergoing chemotherapy for malignant lymphoma or multiple myeloma","volume":"85","year":"2013","journal-title":"J Med Virol"},{"key":"hep29082-bib-0025-20241017","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1002\/hep.26718","article-title":"Chemotherapy\u2010induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study","volume":"59","year":"2014","journal-title":"Hepatology"},{"key":"hep29082-bib-0026-20241017","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s15010-009-9019-1","article-title":"Management of hepatitis B virus reactivation in patients with hematological malignancies treated with chemotherapy","volume":"38","year":"2010","journal-title":"Infection"},{"key":"hep29082-bib-0027-20241017","first-page":"1296","article-title":"Hepatitis B virus reactivation after fludarabine\u2010based regimens for indolent non\u2010Hodgkin's lymphomas: high prevalence of acquired viral genomic mutations","volume":"88","year":"2003","journal-title":"Haematologica"},{"key":"hep29082-bib-0028-20241017","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/0016-5085(91)90599-G","article-title":"Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study","volume":"100","year":"1991","journal-title":"Gastroenterology"},{"key":"hep29082-bib-0029-20241017","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1053\/j.gastro.2006.04.015","article-title":"Kinetics and risk of de novo hepatitis B infection in HBsAg\u2010negative patients undergoing cytotoxic chemotherapy","volume":"131","year":"2006","journal-title":"Gastroenterology"},{"key":"hep29082-bib-0030-20241017","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/s12185-015-1750-z","article-title":"Reactivation of hepatitis B virus (HBV) infection in adult T\u2010cell leukemia\u2010lymphoma patients with resolved HBV infection following systemic chemotherapy","volume":"101","year":"2015","journal-title":"Int J Hematol"},{"key":"hep29082-bib-0031-20241017","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1111\/liv.12838","article-title":"Hepatitis B reactivation in multiple myeloma patients with resolved hepatitis B undergoing chemotherapy","volume":"35","year":"2015","journal-title":"Liver Int"},{"key":"hep29082-bib-0032-20241017","first-page":"225","article-title":"Hepatitis B virus reactivation and hepatitis in diffuse large B\u2010cell lymphoma patients with resolved hepatitis B receiving rituximab\u2010containing chemotherapy: risk factors and survival","volume":"34","year":"2015","journal-title":"Chin J Cancer"},{"key":"hep29082-bib-0033-20241017","doi-asserted-by":"crossref","first-page":"e0126037","DOI":"10.1371\/journal.pone.0126037","article-title":"High risk of hepatitis B reactivation among patients with acute myeloid leukemia","volume":"10","year":"2015","journal-title":"PLoS One"},{"key":"hep29082-bib-0034-20241017","first-page":"376","article-title":"Prospective evaluation of seropositive occult hepatitis B viral infection in lymphoma patients receiving chemotherapy","volume":"17","year":"2011","journal-title":"Hong Kong Med J"},{"key":"hep29082-bib-0035-20241017","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/cncr.24742","article-title":"Hepatitis B virus reactivation and role of antiviral prophylaxis in lymphoma patients with past hepatitis B virus infection who are receiving chemoimmunotherapy","volume":"116","year":"2010","journal-title":"Cancer"},{"key":"hep29082-bib-0036-20241017","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1600-0609.2010.01474.x","article-title":"Low incidence of hepatitis B virus reactivation during chemotherapy among diffuse large B\u2010cell lymphoma patients who are HBsAg\u2010negative\/HBcAb\u2010positive: a multicenter retrospective study","volume":"85","year":"2010","journal-title":"Eur J Haematol"},{"key":"hep29082-bib-0037-20241017","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1200\/JCO.2012.48.5938","article-title":"Randomized controlled trial of entecavir prophylaxis for rituximab\u2010associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B","volume":"31","year":"2013","journal-title":"J Clin Oncol"},{"key":"hep29082-bib-0038-20241017","first-page":"1","article-title":"Recommendations for identification and public health management of persons with chronic hepatitis B virus infection","volume":"57","year":"2008","journal-title":"MMWR Recomm Rep"},{"key":"hep29082-bib-0039-20241017","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s40880-015-0015-9","article-title":"Hepatitis B virus reactivation and hepatitis in diffuse large B\u2010cell lymphoma patients with resolved hepatitis B receiving rituximab\u2010containing chemotherapy: risk factors and survival","volume":"34","year":"2015","journal-title":"Chin J Cancer"},{"key":"hep29082-bib-0040-20241017","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.jcv.2013.03.010","article-title":"Risk of hepatitis B virus (HBV) reactivation in non\u2010Hodgkin lymphoma patients receiving rituximab\u2010chemotherapy: a meta\u2010analysis","volume":"57","year":"2013","journal-title":"J Clin Virol"},{"key":"hep29082-bib-0041-20241017","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1007\/s00277-012-1405-6","article-title":"Analysis of hepatitis B surface antibody titers in B cell lymphoma patients after rituximab therapy","volume":"91","year":"2012","journal-title":"Ann Hematol"},{"key":"hep29082-bib-0042-20241017","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/tid.12283","article-title":"Hepatitis B virus (HBV) reverse seroconversion (RS) can be prevented even in non\u2010responders to hepatitis B vaccine after allogeneic stem cell transplantation: long\u2010term analysis of intervention in RS with vaccine for patients with previous HBV infection","volume":"16","year":"2014","journal-title":"Transpl Infect Dis"},{"key":"hep29082-bib-0043-20241017","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1016\/j.bbmt.2008.08.007","article-title":"HB vaccination in the prevention of viral reactivation in allogeneic hematopoietic stem cell transplantation recipients with previous HBV infection","volume":"14","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"hep29082-bib-0044-20241017","doi-asserted-by":"crossref","first-page":"30","DOI":"10.7326\/M15-1121","article-title":"Hepatitis B virus reactivation and prophylaxis during solid tumor chemotherapy: a systematic review and meta\u2010analysis","volume":"164","year":"2016","journal-title":"Ann Intern Med"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.29082","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-201708000-00011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T23:58:03Z","timestamp":1729209483000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-201708000-00011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,22]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.29082","relation":{},"ISSN":["0270-9139","1527-3350"],"issn-type":[{"value":"0270-9139","type":"print"},{"value":"1527-3350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,22]]},"assertion":[{"value":"2016-05-04","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-12-17","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}